APO-TELMISARTAN 80 MG
TELMISARTAN : 80 MG · DIN 02420090 · APOTEX INC
Health Canada status: CANCELLED POST MARKET
What is APO-TELMISARTAN?
APO-TELMISARTAN 80 MG contains TELMISARTAN : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02420090, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-TELMISARTAN used for?
APO-TELMISARTAN (telmisartan tablets) is indicated for the treatment of mild to moderate essential hypertension in adults. APO-TELMISARTAN is also indicated to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in adults 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02420090 |
|---|---|
| Brand name | APO-TELMISARTAN |
| Generic / active ingredient | TELMISARTAN : 80 MG |
| Manufacturer | APOTEX INC |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA07 TELMISARTAN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Apr-2025 |
How is it administered?
Hypertension: 80 mg once daily. Cardiovascular risk reduction: 80 mg once daily. Hepatic impairment: Starting dose 40 mg. Take with or without food. Swallow whole with liquid.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
APO-TELMISARTAN 40 mg tablets, USP: Blister packs of 30 tablets and bottle packs of 100 and 500 tablets. APO-TELMISARTAN 80 mg tablets, USP: Blister packs of 30 tablets and bottle packs of 100 and 500 tablets.
Contraindications
Hypersensitivity; Pregnancy; Breast-feeding; Concomitant use with aliskiren in patients with diabetes or renal impairment; Hereditary fructose intolerance (contains meglumine and mannitol).
Warnings and precautions
Serious Warning: Fetal toxicity. Risk of angioedema (can be fatal). Hypotension in volume/sodium-depleted patients. Dual blockade of RAS increases risk of hypotension and renal failure.
Is TELMISARTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SIVEM PHARMACEUTICALS ULC, last seen 13 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09CA07 TELMISARTAN. 26 of 52 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-TELMISARTAN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02407485 |
| ACH-TELMISARTAN | 80 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02407493 |
| AG-TELMISARTAN | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02484536 |
| AG-TELMISARTAN | 80 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02484544 |
| AURO-TELMISARTAN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02453568 |
| AURO-TELMISARTAN | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02453576 |
| JAMP TELMISARTAN | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02386755 |
| JAMP TELMISARTAN | 80 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02386763 |
| MICARDIS 40MG TAB | 40 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02240769 |
| MICARDIS 80MG TAB | 80 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02240770 |
Who else supplies TELMISARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TELMISARTAN appears in 482 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.